EUVIMEDEUVIMED entdecken
Crossref

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Kazan medical journal · 15.06.2026 · 107 (3) · 479-480

DOI: 10.17816/kmj707876 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kazan medical journal, online erschienen am 15.06.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This publication is the Russian translation of the Plain Language Summary (PLS) of the Cochrane Systematic Review: Nonino F, Minozzi S, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C, Gonzalez-Lorenzo M, Vignatelli L, Filippini G, Richard E. Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Cochrane Database of Systematic Reviews. 2026. Issue 4. Art. No.: CD016297. DOI: 10.1002/14651858.CD016297

Zitieren

APA

(2026). Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Kazan medical journal, 107(3), 479-480. https://doi.org/10.17816/kmj707876

Vancouver

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. Kazan medical journal. 2026;107(3):479-480. doi:10.17816/kmj707876

BibTeX
@article{euvimed2026,
  title = {Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease},
  journal = {Kazan medical journal},
  year = {2026},
  volume = {107},
  number = {3},
  pages = {479--480},
  doi = {10.17816/kmj707876}
}
Kostenlos starten →